GO:0090068 positive regulation of cell cycle process: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090068 describes any process that increases the rate, frequency or extent of the cellular events driving successive rounds of cell replication.
• MYC is a master positive regulator that amplifies cell cycle progression by activating cyclins, CDKs and E2F target genes.
• p53 acts as a context-dependent positive regulator of cell cycle checkpoints and arrest, illustrating that positive regulation can be either proliferative or protective.
• Mitochondrial proteins such as SLC25A43 can positively regulate cell cycle progression, linking metabolism to division.
• Telomere dysfunction can trigger p21-mediated cell-cycle arrest, showing that positive regulators of arrest are also part of this ontology.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test causal roles of candidate positive regulators [1,2].
Description
GO:0090068, positive regulation of cell cycle process, is a Gene Ontology biological process term that captures any molecular event that increases the rate, frequency or extent of the biochemical and morphological phases occurring during successive cell replication or nuclear replication events. This term is central to understanding how cells decide to divide, pause or arrest, and it encompasses both proliferative drivers and checkpoint-enforcing activities that positively regulate cell cycle progression or arrest. Researchers studying cancer, developmental biology, immunology and regenerative medicine routinely interrogate this term because misregulation of positive regulators underlies uncontrolled proliferation, failed differentiation and therapy resistance [1,2]. The ontology deliberately focuses on the direction of regulation rather than on a single gene, so both oncogenes such as MYC and tumor suppressors such as TP53 can participate depending on context [1,2]. Experimental evidence from mitochondrial, telomere and viral systems further shows that positive regulation of cell cycle process integrates metabolic, structural and environmental cues [5,6,7]. Consequently, GO:0090068 serves as a powerful annotation hub for interpreting transcriptomic, proteomic and CRISPR screening data.
positive regulation of cell cycle process At A Glance
| GO ID | GO:0090068 |
|---|---|
| GO term | positive regulation of cell cycle process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate, frequency or extent of cell cycle progression or checkpoint enforcement [1,2] |
| Representative positive regulators | MYC, CCND1, CDK4/6, E2F1, SLC25A43, p21 (context-dependent) [1,2,5,6] |
| Associated diseases | Cancer, cardiomyocyte arrest, HIV-1 pathogenesis, developmental disorders [2,6,7] |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, Ribo-seq, imaging, flow cytometry [1,2,8] |
What Is GO:0090068?
In plain terms, GO:0090068 describes any process that makes the cell cycle go faster, more often or further along its normal sequence of biochemical and morphological steps. The official QuickGO definition states: Any process that increases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. This means the term is not restricted to a single phase; it covers positive regulation of G1, S, G2, M and checkpoint transitions, as long as the net effect is to promote progression through the cycle [1,2].
Why Is positive regulation of cell cycle process Important in Cell Biology?
Positive regulation of cell cycle process is fundamental because it determines whether a cell proliferates, arrests or dies, and its dysregulation is a hallmark of cancer and many other diseases [1,2]. Understanding which genes positively regulate the cycle, and under what conditions, allows researchers to identify therapeutic targets, interpret genome-wide screens and design precise CRISPR models that distinguish drivers from passengers [1,2,8].
• Cancer: oncogenes such as MYC and cyclin D/CDK complexes drive uncontrolled proliferation by positively regulating cell cycle progression.
• Tumor suppression: p53 can positively regulate cell cycle checkpoints and arrest, preventing propagation of damaged DNA.
• Metabolism: mitochondrial carriers such as SLC25A43 positively regulate cell cycle progression, linking energy metabolism to division.
• Cardiac biology: postnatal telomere dysfunction induces p21-mediated cardiomyocyte cell-cycle arrest, a form of positive regulation of arrest.
• Infection: HIV-1 manipulates cell cycle checkpoints, and positive regulators of these checkpoints influence viral pathogenesis.
• Transcriptomics: cell-cycle-dependent gene modules require careful regression modeling to separate true positive regulators from passive markers.
• Drug development: CDK4/6 inhibitors and other agents target positive regulators of the cell cycle [1,2].
• Stem cell and regenerative medicine: controlled positive regulation is needed for expansion and differentiation [1,6].
• Immuno-oncology: lymphatic drainage and immune surveillance intersect with proliferative control in brain tumors.
• Antibody-drug conjugates: agents such as brentuximab vedotin target dividing cells, relying on cell cycle context.
What Happens During positive regulation of cell cycle process?
G1 phase promotion and restriction point override
In simple terms: The cell decides to start a new division cycle by pushing past a checkpoint called the restriction point.
Positive regulation of cell cycle process frequently begins in G1, where MYC amplifies the expression of cyclins, CDKs and E2F target genes, thereby increasing the rate and extent of progression into S phase. This MYC-driven transcriptional program is a canonical example of how a single factor can positively regulate multiple cell cycle phases. In parallel, p53 can positively regulate G1 checkpoint enforcement, preventing inappropriate S phase entry after DNA damage.
S phase and DNA replication control
In simple terms: Once the cell commits, it must copy its DNA accurately and on schedule.
Positive regulators ensure that DNA replication origins fire efficiently and that replication stress is managed. MYC target genes include replication factors, and their coordinated activation increases the frequency and extent of S phase events. Cell cycle checkpoints, including those influenced by p53, monitor replication fidelity and can positively regulate arrest or repair.
G2/M transition and mitotic entry
In simple terms: The cell checks that everything is ready and then enters mitosis.
Cyclin B-CDK1 complexes are positive regulators of mitotic entry, and their activity is modulated by upstream factors such as MYC and checkpoint kinases [1,2]. Mitochondrial proteins like SLC25A43 have been shown to positively regulate cell cycle progression, including G2/M transit, linking metabolic status to mitotic commitment.
Checkpoint enforcement as positive regulation
In simple terms: Sometimes speeding up the cycle means strengthening the brakes so that damaged cells do not divide.
GO:0090068 includes positive regulation of checkpoint processes. p53 positively regulates cell cycle checkpoints, and its activation can increase the extent of arrest, which is a form of positive regulation of a cell cycle process. Similarly, p21 activation downstream of telomere dysfunction positively regulates cardiomyocyte cell-cycle arrest. Viral pathogens such as HIV-1 manipulate these checkpoints, and positive regulators of checkpoint signaling influence infection outcomes.
Integration of environmental and metabolic cues
In simple terms: The cell cycle does not run in isolation; it listens to signals from metabolism, telomeres and the immune environment.
SLC25A43, a mitochondrial carrier, positively regulates cell cycle progression, demonstrating that metabolic flux can increase the rate of division. Telomere dysfunction activates p21, which positively regulates arrest in postnatal cardiomyocytes. In brain tumors, VEGF-C-driven lymphatic drainage enables immunosurveillance, indirectly influencing proliferative control. These examples show that positive regulation of cell cycle process is a convergence point for diverse physiological inputs [3,5,6].
Key Genes Involved in GO:0090068 positive regulation of cell cycle process
The following genes and proteins are established or context-dependent positive regulators of cell cycle process, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYC | Transcriptionally activates cyclins, CDKs and E2F targets to drive G1/S and beyond | Oncogene; central to proliferation studies and CRISPR KO models |
| TP53 | Positively regulates cell cycle checkpoints and arrest in response to stress | Tumor suppressor; context-dependent positive regulator |
| CDKN1A (p21) | Mediates p53-dependent and telomere-dysfunction-induced cell-cycle arrest | Key effector of positive regulation of arrest |
| CCND1 | Cyclin D1 partners with CDK4/6 to promote G1 progression | Target of MYC; biomarker in cancer |
| CDK4 | Catalytic partner of cyclin D; phosphorylates RB to promote S phase entry | Drug target; CRISPR point-mutation studies |
| CDK6 | Cyclin D-dependent kinase; positive regulator of G1 progression | Target of inhibitors; knockout models |
| E2F1 | Transcription factor activated by RB phosphorylation; drives S phase genes | Downstream effector of MYC and CDKs |
| SLC25A43 | Mitochondrial carrier that positively regulates cell cycle progression | Links metabolism to division; KO studies |
| VEGFC | Drives lymphatic drainage and immunosurveillance in brain tumors | Indirect modulator of proliferative environment |
| TNFRSF8 (CD30) | Target of brentuximab vedotin; expressed on dividing cells | Antibody-drug conjugate context |
| CDK1 | Cyclin B partner; positive regulator of mitotic entry | Core mitotic kinase; CRISPR models |
| CCNB1 | Cyclin B1; activates CDK1 for G2/M transition | MYC target; proliferation marker |
| RB1 | Retinoblastoma protein; its phosphorylation by CDK4/6 relieves repression of E2F | Tumor suppressor; downstream of positive regulators |
| MDM2 | Negatively regulates p53, indirectly modulating p53-mediated positive regulation of checkpoints | Feedback regulator |
| CDKN2A (p16) | Inhibits CDK4/6, opposing positive regulation of G1 progression | Tumor suppressor; context for positive regulators |
| ATM | DNA damage kinase that activates p53 and checkpoints | Upstream of positive regulation of arrest |
| ATR | Replication stress kinase that activates checkpoints | Positive regulator of checkpoint enforcement |
| HIV-1 Tat | Viral protein that manipulates cell cycle checkpoints | Pathogenesis model |
How Is positive regulation of cell cycle process Regulated?
Positive regulation of cell cycle process is itself regulated at multiple levels. MYC protein stability and activity are controlled by ubiquitin-proteasome pathways, and MYC abundance directly sets the rate of cell cycle gene expression. p53 is stabilized by ATM/ATR signaling after DNA damage, leading to p21 induction and checkpoint enforcement. Mitochondrial function, exemplified by SLC25A43, modulates the metabolic capacity required for cycle progression. Telomere status regulates p21 activation and cardiomyocyte arrest. Viral proteins such as HIV-1 Tat can hijack checkpoint regulators, altering the positive regulation landscape. Finally, transcriptome-wide analyses show that cell-cycle-dependent gene modules are subject to regression-line relationships that reflect underlying regulatory wiring.
positive regulation of cell cycle process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Breast cancer and many other cancers [1,2] | CRISPR knockout and overexpression in cancer cell lines |
| TP53 | Breast cancer progression and therapy resistance | Point-mutation knock-in of hotspot mutations |
| CDKN1A (p21) | Cardiomyocyte cell-cycle arrest after telomere dysfunction | Knockout and tagged knock-in in cardiomyocytes |
| SLC25A43 | Mitochondrial regulation of cell cycle progression | Knockout and rescue in metabolic cell models |
| VEGFC | Brain tumor immunosurveillance | Overexpression and knockout in tumor models |
Cancer: MYC and p53 as opposing positive regulators
In many cancers, MYC is amplified or overexpressed, leading to increased positive regulation of cell cycle process and uncontrolled proliferation. Conversely, p53 loss removes a positive regulator of checkpoint arrest, permitting damaged cells to divide. Breast cancer progression illustrates how p53 status alters the balance between proliferation and arrest, with direct therapeutic implications.
Cardiovascular disease: telomere dysfunction and cardiomyocyte arrest
Postnatal telomere dysfunction induces p21 activation, which positively regulates cardiomyocyte cell-cycle arrest, limiting cardiac regeneration. This demonstrates that positive regulation of cell cycle process can be maladaptive in post-mitotic tissues and is a target for regenerative strategies.
Infectious disease: HIV-1 and checkpoint manipulation
HIV-1 infection perturbs cell cycle checkpoints, and positive regulators of these checkpoints influence viral replication and pathogenesis. Understanding how the virus co-opts or counteracts positive regulation of cell cycle process may reveal new antiviral targets.
Brain tumors and immune surveillance
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours, indirectly affecting the proliferative environment and positive regulation of cell cycle process in tumor cells. This highlights the intersection of immune modulation and cell cycle control.
From positive regulation of cell cycle process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is MYC causally required for G1/S progression? | CRISPR knockout of MYC with rescue |
| Does a p53 point mutation alter checkpoint positive regulation? | Point-mutation knock-in of TP53 hotspot alleles |
| Can SLC25A43 overexpression accelerate the cell cycle? | Overexpression and knockout in mitochondrial reporter lines |
| Does p21 mediate telomere-induced cardiomyocyte arrest? | Knockout of CDKN1A in postnatal cardiomyocytes |
| How does HIV-1 Tat modulate checkpoints? | Knock-in of Tat expression in T-cell lines |
| Which genes positively regulate the cycle in a genome-wide screen? | CRISPR library screening with cell-cycle reporters |
How to Study the positive regulation of cell cycle process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of cell cycle genes | Identifying positive regulators from expression data |
| CRISPR knockout screen | Loss-of-function effects on proliferation | Discovering essential positive regulators |
| CRISPR activation screen | Gain-of-function effects on proliferation | Finding sufficiency of candidate genes |
| Flow cytometry | DNA content and cell cycle phase distribution | Quantifying positive regulation of transitions |
| Live-cell imaging | Dynamics of cell cycle reporters | Measuring rate and frequency of division |
| Phosphoproteomics | CDK substrate phosphorylation | Mapping signaling downstream of positive regulators |
| Ribo-seq | Translation efficiency of cell cycle mRNAs | Linking MYC-driven transcription to protein output |
| CRISPR point-mutation knock-in | Effect of specific alleles on checkpoint function | Modeling p53 mutations in cancer |
Transcriptomic profiling of cell cycle modules
RNA-seq and regression-line analyses can identify cell-cycle-dependent gene modules and distinguish positive regulators from passive markers. Comparing transcriptomes across synchronized populations reveals which genes increase the rate or extent of cycle progression.
CRISPR screening for positive regulators
Genome-wide CRISPR knockout and activation screens with cell-cycle reporters enable unbiased discovery of positive regulators of cell cycle process [1,2]. Hits can be validated by targeted knockout or overexpression.
Imaging and flow cytometry
Live-cell imaging of fluorescent cell cycle reporters and flow cytometry with DNA dyes measure the rate and frequency of cycle transitions, providing direct readouts of positive regulation [1,6].
Proteomic and phosphoproteomic analysis
Mass spectrometry can quantify cyclin and CDK phosphorylation events that mark positive regulation of cell cycle process, revealing downstream signaling changes [1,2].
How CRISPR Can Be Used to Study GO:0090068 positive regulation of cell cycle process
Knockout
CRISPR knockout of candidate positive regulators such as MYC or CDK4 allows researchers to test whether loss reduces the rate or extent of cell cycle progression. Knockout of CDKN1A can reveal its role in p21-mediated arrest.
Point Mutation
Point-mutation knock-in of TP53 hotspot alleles enables precise modeling of how specific mutations alter positive regulation of checkpoints. This approach distinguishes loss-of-function from gain-of-function effects.
Knock-in
Tagged knock-in of cell cycle regulators with fluorescent or epitope tags permits real-time tracking of protein localization and dynamics during positive regulation [1,6]. Knock-in of viral factors such as HIV-1 Tat can model pathogen-driven checkpoint manipulation.
Overexpression
CRISPR activation or cDNA overexpression of genes like SLC25A43 or VEGFC tests sufficiency for accelerating cell cycle progression or altering the tumor microenvironment [3,5]. Overexpression of MYC is a classic model of oncogene-driven proliferation.
How EDITGENE Supports positive regulation of cell cycle process Research
Researchers studying positive regulation of cell cycle process-related genes often need to determine whether a candidate gene is causally involved in driving or restraining proliferation, and CRISPR-based models provide the most direct way to establish causality [1,2].
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cell cycle process research.
Frequently Asked Questions About positive regulation of cell cycle process
What is GO:0090068 positive regulation of cell cycle process?
GO:0090068 is a Gene Ontology biological process term describing any process that increases the rate, frequency or extent of the biochemical and morphological events occurring during successive cell replication or nuclear replication events [1,2].
What genes are involved in positive regulation of cell cycle process?
Key genes include MYC, CCND1, CDK4, CDK6, E2F1, CDK1, CCNB1, TP53, CDKN1A, SLC25A43 and VEGFC, among others [1,2,3,5,6].
How does MYC positively regulate the cell cycle?
MYC transcriptionally activates cyclins, CDKs and E2F target genes, increasing the rate and extent of G1/S and subsequent phase progression.
Can p53 positively regulate the cell cycle?
Yes, p53 positively regulates cell cycle checkpoints and arrest in response to stress, which is a form of positive regulation of a cell cycle process.
What diseases are linked to positive regulation of cell cycle process?
Cancer, cardiovascular disease with cardiomyocyte arrest, HIV-1 pathogenesis and brain tumor immunosurveillance are linked to this process [2,3,6,7].
How do researchers study positive regulation of cell cycle process?
Methods include CRISPR knockout and activation screens, RNA-seq, Ribo-seq, flow cytometry, live-cell imaging and phosphoproteomics [1,2,6,8].
What is the role of SLC25A43 in the cell cycle?
SLC25A43 is a mitochondrial carrier that positively regulates cell cycle progression, linking metabolism to division.
How does telomere dysfunction affect the cell cycle?
Postnatal telomere dysfunction induces p21 activation, which positively regulates cardiomyocyte cell-cycle arrest.
What CRISPR models are used for cell cycle research?
Knockout, point-mutation knock-in, tagged knock-in, overexpression and CRISPR library screening are commonly used [1,2,6].
Why is GO:0090068 important for cancer research?
Because misregulation of positive regulators such as MYC and p53 drives uncontrolled proliferation or checkpoint evasion, making them therapeutic targets [1,2].
Conclusion
GO:0090068 positive regulation of cell cycle process is a broad yet precise ontology term that captures the many ways cells accelerate, sustain or enforce cell cycle progression and arrest [1,2]. Its study spans cancer, cardiovascular biology, infectious disease and immunology, and relies on CRISPR models, transcriptomics and imaging to establish causality [1,2,6,8]. By integrating authoritative GO annotation with real experimental evidence, researchers can design robust studies and identify actionable targets within this process.
References
- 1. Bretones G et al.. 2015. Myc and cell cycle control.. Biochim Biophys Acta 1849(5):506-16 PMID: 24704206
- 2. Marvalim C et al.. 2023. Role of p53 in breast cancer progression: An insight into p53 targeted therapy.. Theranostics 13(4):1421-1442 PMID: 36923534
- 3. Song E et al.. 2020. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.. Nature 577(7792):689-694 PMID: 31942068
- 4. van de Donk NW et al.. 2012. Brentuximab vedotin.. MAbs 4(4):458-65 PMID: 22684302
- 5. Gabrielson M et al.. 2016. Mitochondrial regulation of cell cycle progression through SLC25A43.. Biochem Biophys Res Commun 469(4):1090-6 PMID: 26721434
- 6. Aix E et al.. 2016. Postnatal telomere dysfunction induces cardiomyocyte cell-cycle arrest through p21 activation.. J Cell Biol 213(5):571-83 PMID: 27241915
- 7. Kurapati KR et al.. 2015. Cell cycle checkpoints and pathogenesis of HIV-1 infection: a brief overview.. J Basic Clin Physiol Pharmacol 26(1):1-11 PMID: 25046311
- 8. Vinogradov AE et al.. 2020. Cell-cycle dependence of transcriptome gene modules: comparison of regression lines.. FEBS J 287(20):4427-4439 PMID: 32083797
